Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
15 mars 2023 06h50 HE
|
Eton Pharmaceuticals
-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or...
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
07 mars 2023 16h05 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
11 janv. 2023 06h50 HE
|
Eton Pharmaceuticals
-- Product previously granted orphan drug designation for methanol poisoning ---- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton...
Eton Pharmaceuticals Reports Third Quarter 2022 Financial Results
10 nov. 2022 16h05 HE
|
Eton Pharmaceuticals
Q3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022Strong sales growth of ALKINDI SPRINKLE® and Carglumic AcidThird commercial product,...
Eton Pharmaceuticals to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
02 nov. 2022 16h05 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals to Present at the LD Micro Main Event XV Conference
18 oct. 2022 06h50 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Rare Disease Product, Betaine Anhydrous for Oral Solution
13 sept. 2022 09h00 HE
|
Eton Pharmaceuticals
-- Expected to be accretive to 2023 earnings -- DEER PARK, Ill., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical...
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
30 août 2022 16h05 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Reports Second Quarter 2022 Financial Results
11 août 2022 16h01 HE
|
Eton Pharmaceuticals
Total Q2 2022 revenue of $7.4 million, up 139% from prior yearRecently launched ALKINDI SPRINKLE® and Carglumic Acid continue to show robust growthDivestiture of hospital products division to focus on...
Eton Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
02 août 2022 08h00 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...